NASDAQ:AGIO

Agios Pharmaceuticals - AGIO Stock Forecast, Price & News

$28.28

-0.29 (-1.02%)

(As of 09/30/2022 09:00 PM ET)

Add

Compare

Today's Range: $28.19
▼
$29.54
50-Day Range: $19.51
▼
$34.14
52-Week Range: $16.75
▼
$50.98

Volume: 639,600 shs
Average Volume: 671,322 shs
Market Capitalization: $1.55 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $51.14

Agios Pharmaceuticals MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.71 Rating Score
Upside/Downside: 80.8% Upside
$51.14 Price Target
Short Interest: Bearish
10.50% of Float Sold Short
Dividend Strength: N/A
Sustainability: -1.09
Upright™ Environmental Score
News Sentiment: 1.22
Based on 6 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($6.89) to ($6.35) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.97 out of 5 stars

Medical Sector

691st out of 1,095 stocks

Pharmaceutical Preparations Industry

335th out of 547 stocks

3.4

Analyst's Opinion

Consensus Rating
Agios Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.71, and is based on 6 buy ratings, no hold ratings, and 1 sell rating.
Price Target Upside/Downside
According to analysts' consensus price target of $51.14, Agios Pharmaceuticals has a forecasted upside of 80.8% from its current price of $28.28.
Amount of Analyst Coverage
Agios Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
10.50% of the float of Agios Pharmaceuticals has been sold short.
Short Interest Ratio / Days to Cover
Agios Pharmaceuticals has a short interest ratio ("days to cover") of 7.5.
Change versus previous month
Short interest in Agios Pharmaceuticals has recently increased by 3.27%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Agios Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Agios Pharmaceuticals does not have a long track record of dividend growth.

4.5

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Agios Pharmaceuticals has received a 69.54% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for physical health" and "Preclinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Agios Pharmaceuticals is -1.09.

2.9

News and Social Media Coverage

News Sentiment
Agios Pharmaceuticals has a news sentiment score of 1.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.83 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 6 news articles for Agios Pharmaceuticals this week, compared to 2 articles on an average week.
Search Interest
Only 6 people have searched for AGIO on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Agios Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 4.48% of the stock of Agios Pharmaceuticals is held by insiders.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Agios Pharmaceuticals are expected to grow in the coming year, from ($6.89) to ($6.35) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Agios Pharmaceuticals is -4.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Agios Pharmaceuticals is -4.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Agios Pharmaceuticals has a P/B Ratio of 1.19. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Agios Pharmaceuticals (NASDAQ:AGIO) Stock

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Receive AGIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Agios Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

AGIO Stock News Headlines

October 2, 2022 | finance.yahoo.com

We Think Agios Pharmaceuticals (NASDAQ:AGIO) Can Afford To Drive Business Growth

September 26, 2022 | ca.finance.yahoo.com

Agios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Financial Officer

September 26, 2022 | bizjournals.com

Five things you need to know today, and that baffling calendar

September 24, 2022 | americanbankingnews.com

Agios Pharmaceuticals (NASDAQ:AGIO) Shares Gap Down to $29.80

September 19, 2022 | marketwatch.com

Agios Pharmaceuticals Names Cecilia Jones as Next Financial Chief

September 19, 2022 | finance.yahoo.com

Agios Appoints Cecilia Jones as Chief Financial Officer

September 18, 2022 | morningstar.com

Agios Pharmaceuticals Gets CHMP Backing for Pyrukynd

September 16, 2022 | nasdaq.com

Agios Says CHMP Adopts Positive Opinion For PYRUKYND To Treat Pyruvate Kinase Deficiency In Adults

September 16, 2022 | marketwatch.com

Agios Pharmaceuticals Gets CHMP Backing for Pyrukynd >AGIO

September 16, 2022 | finance.yahoo.com

Agios Receives Positive CHMP Opinion for PYRUKYND® (mitapivat) for the Treatment of Pyruvate Kinase (PK) Deficiency in Adult Patients

September 16, 2022 | markets.businessinsider.com

Servier leverages Mission Bio's Tapestri® Platform to uncover AML resistance mechanisms in pivotal TIBSOVO® (ivosidenib) clinical trial

September 15, 2022 | apnews.com

Servier leverages Mission Bio’s Tapestri® Platform to uncover AML resistance mechanisms in pivotal TIBSOVO® (ivosidenib) clinical trial

September 8, 2022 | marketwatch.com

Agios Pharmaceuticals's Shares Fall on Upcoming CFO Departure

September 6, 2022 | finance.yahoo.com

A Technical Strategy to 'Buy' Agios Pharmaceuticals

September 2, 2022 | finance.yahoo.com

Agios Pharmaceuticals Stock Clears Key Benchmark, Hitting 90-Plus RS Rating

September 1, 2022 | msn.com

Nutanix, Five Below And Some Other Big Stocks Moving Higher On Thursday

August 24, 2022 | finance.yahoo.com

Agios to Participate in September Investor Conferences

August 19, 2022 | nasdaq.com

Shareholders in Agios Pharmaceuticals (NASDAQ:AGIO) have lost 54%, as stock drops 7.1% this past week

August 18, 2022 | finance.yahoo.com

Agios Announces Publication of Phase 3 ACTIVATE-T Data in The Lancet Haematology Demonstrating Benefits of PYRUKYND® (mitapivat) for Adults with Pyruvate Kinase Deficiency

August 16, 2022 | msn.com

Looking Into Agios Pharmaceuticals Return On Capital Employed

August 15, 2022 | finance.yahoo.com

Agios Appoints Rahul Ballal and Cynthia Smith to Board of Directors

August 11, 2022 | finance.yahoo.com

Agios Announces Publication of Phase 2 Data in The Lancet Demonstrating Safety and Efficacy of PYRUKYND® (mitapivat) in Non-transfusion-dependent α- and β-Thalassemia

August 8, 2022 | finance.yahoo.com

Agios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Executive Officer

August 8, 2022 | finance.yahoo.com

Even after rising 38% this past week, Agios Pharmaceuticals (NASDAQ:AGIO) shareholders are still down 49% over the past five years

August 7, 2022 | seekingalpha.com

Agios Pharmaceuticals, Inc. (AGIO) CEO Jackie Fouse on Q2 2022 Results - Earnings Call Transcript

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive AGIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Agios Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

AGIO Company Calendar

Last Earnings: 8/04/2022
Today: 10/03/2022
Next Earnings (Estimated): 11/02/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:AGIO
CUSIP: N/A
CIK: 1439222
Web: www.agios.com
Phone: (617) 649-8600
Fax: N/A
Employees: 390
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $51.14
High Stock Price Forecast: $96.00
Low Stock Price Forecast: $16.00
Forecasted Upside/Downside: +80.8%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.71
Research Coverage: 7 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($6.72)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $1.60 billion
Net Margins: N/A
Pretax Margin: -5,759.63%
Return on Equity: -29.45%
Return on Assets: -26.54%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 17.98
Quick Ratio: 17.89

Sales & Book Value

Annual Sales: $203.20 million
Price / Sales: 7.63
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $23.79 per share
Price / Book: 1.19

Miscellaneous

Outstanding Shares: 54,818,000
Free Float: 52,362,000
Market Cap: $1.55 billion
Optionable: Optionable
Beta: 1.18

Key Executives

Mr. Jonathan Biller J.D. (Age 57)
CFO & Head of Corp. Affairs
Comp: $804.18k

Dr. Bruce Car Ph.D. (Age 60)
Consultant
Comp: $776.12k

Dr. Sarah Gheuens M.D. (Age 42)
Ph.D., Chief Medical Officer and Head of R&D
Comp: $1.57M

Ms. Richa Poddar (Age 40)
Chief Commercial Officer
Comp: $624.08k

Mr. Brian M. Goff M.B.A. (Age 53)
CEO & Director

Dr. Lewis Clayton Cantley Ph.D. (Age 73)
Co-Founder & Member of Scientific Advisory Board

Dr. Tak Wah Mak D.Sc. (Age 76)
FRSC, Ph.D., Co-Founder & Member of Scientific Advisory Board

Dr. Craig B. Thompson M.D. (Age 69)
Co-Founder & Chairman of Scientific Advisory Board

Dr. Shin-San Su Ph.D. (Age 66)
Co-Founder & Member of Scientific Advisory Board

Mr. T. J. Washburn Jr. (Age 41)
Principal Accounting Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

AGIO Stock - Frequently Asked Questions

Should I buy or sell Agios Pharmaceuticals stock right now?: 7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Agios Pharmaceuticals in the last year. There are currently 1 sell rating and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" AGIO shares.
View AGIO analyst ratings or view top-rated stocks.
What is Agios Pharmaceuticals' stock price forecast for 2022?: 7 Wall Street analysts have issued 12 month price objectives for Agios Pharmaceuticals' stock. Their AGIO share price forecasts range from $16.00 to $96.00. On average, they expect the company's stock price to reach $51.14 in the next twelve months. This suggests a possible upside of 80.8% from the stock's current price.
View analysts price targets for AGIO or view top-rated stocks among Wall Street analysts.
How have AGIO shares performed in 2022?: Agios Pharmaceuticals' stock was trading at $32.87 at the beginning of 2022. Since then, AGIO stock has decreased by 14.0% and is now trading at $28.28.
View the best growth stocks for 2022 here.
When is Agios Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 2nd 2022.
View our AGIO earnings forecast.
How were Agios Pharmaceuticals' earnings last quarter?: Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) announced its quarterly earnings data on Thursday, August, 4th. The biopharmaceutical company reported ($1.68) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.78) by $0.10. The biopharmaceutical company had revenue of $5.58 million for the quarter, compared to analyst estimates of $2.86 million. Agios Pharmaceuticals's quarterly revenue was up 5482.0% on a year-over-year basis. During the same period last year, the firm posted ($1.36) EPS.
What is Jackie Fouse's approval rating as Agios Pharmaceuticals' CEO?: 11 employees have rated Agios Pharmaceuticals Chief Executive Officer Jackie Fouse on Glassdoor.com. Jackie Fouse has an approval rating of 100% among the company's employees. This puts Jackie Fouse in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Agios Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Agios Pharmaceuticals investors own include Gilead Sciences (GILD), Micron Technology (MU), Alibaba Group (BABA), bluebird bio (BLUE), Pfizer (PFE), Vertex Pharmaceuticals (VRTX), NVIDIA (NVDA), Tesla (TSLA) and Netflix (NFLX).
What is Agios Pharmaceuticals' stock symbol?: Agios Pharmaceuticals trades on the NASDAQ under the ticker symbol "AGIO."
How do I buy shares of Agios Pharmaceuticals?: Shares of AGIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Agios Pharmaceuticals' stock price today?: One share of AGIO stock can currently be purchased for approximately $28.28.
How much money does Agios Pharmaceuticals make?: Agios Pharmaceuticals (NASDAQ:AGIO) has a market capitalization of $1.55 billion and generates $203.20 million in revenue each year. The biopharmaceutical company earns $1.60 billion in net income (profit) each year or ($6.72) on an earnings per share basis.
How many employees does Agios Pharmaceuticals have?: The company employs 390 workers across the globe.
How can I contact Agios Pharmaceuticals?: Agios Pharmaceuticals' mailing address is 88 SIDNEY STREET, CAMBRIDGE MA, 02139. The official website for the company is www.agios.com. The biopharmaceutical company can be reached via phone at (617) 649-8600 or via email at investors@agios.com.

This page (NASDAQ:AGIO) was last updated on 10/3/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Agios Pharmaceuticals - AGIO Stock Forecast, Price & News

Agios Pharmaceuticals MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability